Takeda Pharmaceutical Company Limited (TAK) Key Metrics
TAK key metrics, FY2017–FY2026
Fiscal year ended March 31, 2026 · Japanese yenTAK returns How much profit the business earns on the capital it uses.
TAK financial health Debt, liquidity and how easily interest is covered.
TAK efficiency & capital use Working capital cycle and where the cash goes.
TAK returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
TAK debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
TAK cash returned to shareholders
TAK key metrics in Japanese yen
FY2017–FY2026| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 2.8% | 1.5% | 2.1% | 5.3% | 4.2% | 7.6% | 0.9% | 3.0% | 9.6% | 6.0% |
| Return on invested capital (ROIC) | 3.7% | 1.9% | 2.0% | 4.3% | 3.9% | 5.7% | 0.8% | 3.2% | 7.9% | 5.2% |
| Return on assets (ROA) | 1.4% | 0.7% | 1.0% | 2.3% | 1.8% | 2.9% | 0.3% | 1.2% | 4.4% | 2.8% |
| Return on tangible assets | 3.3% | 2.0% | 2.7% | 6.5% | 4.6% | 7.6% | 1.0% | 2.2% | 9.1% | 5.1% |
| Free cash flow margin | 13.1% | 14.8% | 5.5% | 8.5% | 26.3% | 24.2% | 13.7% | 9.3% | 14.1% | 8.6% |
| Income quality (OCF / net income) | 5.12 | 9.80 | 4.97 | 3.08 | 4.88 | 2.69 | 15.14 | 3.01 | 2.02 | 2.27 |
| Financial health | ||||||||||
| Total debt | ¥4.90T | ¥4.52T | ¥4.84T | ¥4.38T | ¥4.35T | ¥4.64T | ¥5.09T | ¥5.75T | ¥985.66B | ¥1.14T |
| Cash & short-term investments | ¥597.63B | ¥405.59B | ¥472.89B | ¥553.70B | ¥875.00B | ¥1.00T | ¥653.44B | ¥725.37B | ¥375.17B | ¥376.14B |
| Net debt | ¥4.31T | ¥4.11T | ¥4.37T | ¥3.83T | ¥3.47T | ¥3.63T | ¥4.44T | ¥5.03T | ¥610.49B | ¥768.75B |
| Debt / equity | 0.63 | 0.65 | 0.67 | 0.69 | 0.76 | 0.90 | 1.08 | 1.11 | 0.49 | 0.60 |
| Debt / assets | 0.32 | 0.32 | 0.32 | 0.31 | 0.33 | 0.36 | 0.40 | 0.41 | 0.24 | 0.26 |
| Net debt / EBITDA | 3.13 | 3.39 | 3.56 | 2.98 | 2.93 | 3.69 | 6.61 | 10.83 | 1.70 | 2.59 |
| Current ratio | 1.27 | 1.01 | 1.11 | 0.97 | 1.21 | 1.53 | 1.13 | 1.21 | 1.46 | 0.92 |
| Quick ratio | 0.70 | 0.52 | 0.58 | 0.57 | 0.81 | 1.10 | 0.79 | 0.82 | 1.17 | 0.76 |
| Interest coverage | 1.5 | 2.5 | 201.5 | 4.2 | 3.8 | 3.9 | 68.8 | 4.3 | 7.6 | 6.7 |
| Working capital | ¥663.84B | ¥14.67B | ¥245.48B | −¥83.98B | ¥447.91B | ¥939.72B | ¥293.53B | ¥539.73B | ¥341.30B | −¥105.43B |
| Invested capital | ¥12.11T | ¥11.04T | ¥11.64T | ¥10.18T | ¥9.15T | ¥8.81T | ¥9.16T | ¥10.19T | ¥2.61T | ¥2.66T |
| Tangible asset value | −¥1.46T | −¥2.02T | −¥2.41T | −¥2.71T | −¥2.54T | −¥2.77T | −¥3.46T | −¥3.86T | −¥26.10B | −¥139.58B |
| Net current asset value | −¥4.61T | −¥4.79T | −¥5.28T | −¥5.21T | −¥4.90T | −¥5.02T | −¥5.62T | −¥5.66T | −¥1.01T | −¥1.15T |
| Capital allocation | ||||||||||
| Dividends paid | ¥311.90B | ¥302.50B | ¥287.19B | ¥279.42B | ¥283.67B | ¥283.36B | ¥282.58B | ¥142.95B | ¥141.89B | ¥141.69B |
| Share buybacks (net) | ¥51.60B | ¥51.86B | ¥2.33B | ¥26.93B | ¥77.53B | ¥2.14B | ¥3.74B | ¥1.17B | ¥18.76B | ¥23.12B |
| Dividend payout ratio | 153.4% | 280.3% | 199.3% | 88.1% | 123.3% | 75.4% | 638.7% | 131.0% | 75.9% | 123.3% |
| Dividends + buybacks / free cash flow | 58.0% | 52.3% | 122.9% | 89.2% | 38.5% | 36.9% | 63.3% | 74.2% | 64.4% | 110.4% |
| Capex / revenue | 8.7% | 8.3% | 11.3% | 15.7% | 5.2% | 7.4% | 6.6% | 6.4% | 7.2% | 6.5% |
| Capex / operating cash flow | 39.8% | 35.9% | 67.1% | 64.9% | 16.6% | 23.4% | 32.5% | 40.8% | 33.9% | 42.9% |
| Capex / depreciation | 0.58 | 0.50 | 0.66 | 0.95 | 0.32 | 0.42 | 0.37 | 0.54 | 0.70 | 0.65 |
| Stock-based compensation / revenue | 1.5% | 1.6% | 1.7% | 1.5% | 1.2% | 1.2% | 0.9% | 1.0% | 1.1% | 0.9% |
| R&D / revenue | 15.0% | 15.9% | 17.1% | 15.7% | 14.7% | 14.3% | 15.0% | 17.6% | 18.4% | 18.0% |
| SG&A / revenue | 22.7% | 24.1% | 24.7% | 24.8% | 24.8% | 27.4% | 29.3% | 34.2% | 35.5% | 35.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 61.3 | 56.7 | 59.0 | 63.7 | 78.6 | 91.2 | 85.1 | 102.5 | 90.0 | 92.2 |
| Days of inventory on hand | 204.5 | 280.3 | 280.0 | 269.9 | 265.0 | 277.8 | 292.5 | 331.9 | 161.6 | 156.9 |
| Days payables outstanding | 62.6 | 72.6 | 80.0 | 88.5 | 87.1 | 81.4 | 71.0 | 95.7 | 137.8 | 141.0 |
| Cash conversion cycle (days) | 203.2 | 264.4 | 259.1 | 245.1 | 256.5 | 287.5 | 306.5 | 338.7 | 113.9 | 108.1 |
| Receivables turnover | 5.95 | 6.44 | 6.18 | 5.73 | 4.64 | 4.00 | 4.29 | 3.56 | 4.05 | 3.96 |
| Payables turnover | 5.83 | 5.03 | 4.56 | 4.12 | 4.19 | 4.48 | 5.14 | 3.81 | 2.65 | 2.59 |
| Inventory turnover | 1.78 | 1.30 | 1.30 | 1.35 | 1.38 | 1.31 | 1.25 | 1.10 | 2.26 | 2.33 |
| Asset turnover | 0.32 | 0.31 | 0.29 | 0.30 | 0.27 | 0.25 | 0.25 | 0.23 | 0.42 | 0.42 |
| Average receivables | ¥802.70B | ¥711.43B | ¥689.65B | ¥703.04B | ¥768.55B | ¥798.82B | ¥767.02B | ¥588.96B | ¥436.79B | ¥437.67B |
| Average payables | ¥400.96B | ¥314.20B | ¥313.70B | ¥301.69B | ¥264.02B | ¥221.87B | ¥211.99B | ¥173.03B | ¥187.16B | ¥215.86B |
| Average inventory | ¥1.31T | ¥1.21T | ¥1.10T | ¥919.81B | ¥803.52B | ¥756.74B | ¥873.17B | ¥599.84B | ¥219.62B | ¥240.15B |
| Intangibles / total assets | 59.7% | 62.9% | 64.1% | 64.9% | 62.4% | 61.5% | 63.8% | 65.0% | 49.8% | 47.9% |
Computed from TAK's annual financial statements (latest annual report filed June 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Japanese yen; data from EODHD. Averages use the opening and closing balance of each year.
TAK valuation and financial ratios
Takeda Pharmaceutical earned a return on equity of 2.8% and a return on invested capital of 3.7% in fiscal 2026. It ended the year with ¥4.90 trillion of debt and ¥597.6 billion in cash and short-term investments, net debt of ¥4.31 trillion. It returned ¥363.5 billion to shareholders: ¥311.9 billion in dividends and ¥51.6 billion in share buybacks, 58% of free cash flow.
See the TAK income statement, the TAK chart for price history, or the TAK stock overview for the latest quote and news.
TAK key metrics FAQ
What is Takeda Pharmaceutical's return on equity?
Takeda Pharmaceutical's return on equity (ROE) was 2.8% in fiscal 2026: net income of ¥203.3 billion on average shareholders' equity of ¥7.37 trillion.
What is Takeda Pharmaceutical's ROIC?
Takeda Pharmaceutical's return on invested capital was 3.7% in fiscal 2026, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Takeda Pharmaceutical have?
Takeda Pharmaceutical had total debt of ¥4.90 trillion at the end of fiscal 2026, a debt-to-equity ratio of 0.63 and ¥4.31 trillion of net debt (3.13 times EBITDA).
Does Takeda Pharmaceutical buy back its shares?
Yes. Takeda Pharmaceutical spent ¥51.6 billion on net share repurchases in fiscal 2026.
What is Takeda Pharmaceutical's current ratio?
Takeda Pharmaceutical's current ratio was 1.27 at the end of fiscal 2026: current assets were 1.27 times current liabilities.